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Available online xxxxLoss of functionmutations of the proteinMICU1, a regulator of mitochondrial Ca2+ uptake, cause a neuronal and
muscular disorder characterised by impaired cognition, muscle weakness and an extrapyramidalmotor disorder.
We have shown previously that MICU1 mutations cause increased resting mitochondrial Ca2+ concentration
([Ca2+]m). We now explore the functional consequences of MICU1mutations in patient derived ﬁbroblasts in
order to clarify the underlying pathophysiology of this disorder. We propose that deregulation of mitochondrial
Ca2+ uptake through loss of MICU1 raises resting [Ca2+]m, initiating a futile Ca
2+ cycle, whereby continuousmi-
tochondrial Ca2+ inﬂux is balanced by Ca2+ efﬂux through the sodium calcium exchanger (NLCXm). Thus, inhi-
bition ofNCLXmbyCGP-37157 caused rapidmitochondrial Ca2+accumulation inpatient but not control cells.We
suggest that increased NCLX activity will increase sodium/proton exchange, potentially undermining oxidative
phosphorylation, although this is balanced by dephosphorylation and activation of pyruvate dehydrogenase
(PDH) in response to the increased [Ca2+]m. Consistent with this model, while ATP content in patient derived
or control ﬁbroblasts was not different, ATP increased signiﬁcantly in response to CGP-37157 in the patient but
not the control cells. In addition, EMRE expression levels were altered in MICU1 patient cells compared to the
controls. The MICU1 mutations were associated with mitochondrial fragmentation which we show is related
to altered DRP1 phosphorylation. Thus, MICU1 serves as a signal–noise discriminator in mitochondrial calcium
signalling, limiting the energetic costs of mitochondrial Ca2+ signalling which may undermine oxidative
phosphorylation, especially in tissues with highly dynamic energetic demands. This article is part of a Special
Issue entitled: ECS Meeting edited by Claus Heizmann, Joachim Krebs and Jacques Haiech.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
Mitochondria
Calcium
MICU1
PDH1. Introduction
Calcium signalling is fundamental to much of cell physiology, as a
rise in cytosolic calcium ion concentration ([Ca2+]c) drives an astonish-
ing array of physiological processes. These include contraction in skele-
tal, cardiac and smoothmuscle, secretion from all cell types, while Ca2+
signals play key roles in learning and memory, in cell migration, and
triggering the earliest phases of development following fertilisation of
the oocyte. It has been clear since the pioneering work of Lehninger,
Attardi, Carafoli, Deluca and Crompton that mitochondria have a huge
capacity to accumulate calcium ions (Ca2+) [1–5]. The last two decades
have seen thewidespread recognition that all physiological calcium sig-
nals so far studied are associatedwith the accumulation of Ca2+ intomi-
tochondria mediated by mitochondrial Ca2+ uptake pathways [6].ting edited by Claus Heizmann,
. This is an open access article under
thological consequences ofMI
.org/10.1016/j.bbamcr.2017.0The accumulation of Ca2+ bymitochondria underpins a complex re-
ciprocal dialogue with the Ca2+ signalling machinery that operates on
many levels. Thus, the spatial buffering of Ca2+ by mitochondria serves
to regulate the spatiotemporal patterning of Ca2+ signals [7], which
may have a profound impact on downstreamCa2+dependent signalling
pathways. At the same time, a rise in [Ca2+]c and an increase in matrix
Ca2+ concentration ([Ca2+]m) both have metabolic consequences. A
rise in [Ca2+]c will drive an increase in ATP consumption, but simulta-
neously stimulates themalate-aspartate shuttle, ARALAR, driving an in-
crease in intramitochondrial NADH that stimulates respiration and
increases the rate of ATP synthesis [8]. This is ampliﬁed by the impact
of a rise in [Ca2+]m, which stimulates the activity of the three rate limit-
ing enzymes of the TCA cycle, each ofwhich ismodulated by Ca2+, again
increasing the rate at which reduced NADH is generated by the cycle,
and so driving an increased rate of ATP synthesis [9]. This increased ac-
tivity is balanced and supported by stimulation of the ATP synthase it-
self, perhaps less clearly characterised [10–14]. Thus, the dialogue
betweenmitochondria and Ca2+ signalling reﬂects a simple and elegant
mechanism that serves to balance an increased rate of ATP provision to
match the increased demand that inevitably accompanies the processesthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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contraction, secretion, migration, or gene expression.
Mitochondrial Ca2+ uptake also drives cell death under conditions of
cellular Ca2+ overload, as supraphysiological mitochondrial Ca2+ accu-
mulation can trigger opening of a large conductance pore in the inner
mitochondrial membrane, the mitochondrial permeability transition
pore (mPTP) [15–17], especially when coincident with oxidative stress.
Ca2+ induced cell death has been most extensively characterised in is-
chaemia reperfusion injury in the heart [18,19], but probably also
plays roles in in neurodegenerative disorders such as ALS, Alzheimer's
disease and Parkinson's disease [20], possibly in demyelinating disease
(multiple sclerosis), in pancreatitis, in several forms ofmuscular dystro-
phy and myopathy [21] and in pathological changes associated with di-
abetes [22,23].
Ca2+ homeostasis within the mitochondrial matrix is maintained
through Ca2+ uptake and efﬂux pathways. The primary mechanism
for Ca2+ efﬂux that normally maintains a low matrix Ca2+ concentra-
tion ([Ca2+]m) is the Na+/Ca2+ exchanger, recently identiﬁed as NCLX
[24]. While the capacity of energised mitochondria to accumulate
Ca2+wasﬁrst observed in the 1960s, themolecular identity of the chan-
nel thatmediates Ca2+ import intomitochondriawas identiﬁed only re-
cently as the well conserved mitochondrial Ca2+ uniporter (MCU) [25,
26], a ruthenium-red sensitive channel in the inner mitochondrial
membrane (IMM). The MCU consists of two highly conserved trans-
membrane domains connected by the DIME motif, which are predicted
to oligomerise and form a tetrameric gated ion channel [27]. Knockout
or silencing of the MCU in most mouse strains is embryonically lethal,
but viable knockouts have been generated in an outbred strain [28]. In
this model, MCU knockout severely reduces calcium uptake, but ap-
pears to have surprisingly little impact on mitochondrial bioenergetic
function [25,26,29]. The globalMCU knockout (MCUKO)mice are small-
er than littermates, and showa reduced power and reduced activity on a
treadmill but otherwise the phenotype is very mild. The conditional
knockout in the heart shows a reduced capacity to respond to increased
drive [30].
The MCU complex consists of the MCU in association with several
proteins which are thought to play a regulatory role, and some of
which show variation in expression in different tissues [27,31]. This
could be important in addressing the different metabolic demands of
different tissues. MCU associated proteins include MCUb, MICU1,
MICU2 and MICU3 and EMRE, and possibly some other proteins
whose contribution remains a little more controversial (for example,
MCUR1, SLC25A23) [32,33]. Of these components, MICU1 and MICU2
(Mitochondrial Calcium Uptake 1) play signiﬁcant roles in regulating
calcium uptake. MICU1 has two highly conserved EF hand motifs,
which confer sensitivity to cytosolic Ca2+ concentration [Ca2+]c [34].
MICU2 also has Ca2+ sensing EF hands, which allow MICU2 to form di-
mers upon binding to Ca2+. The two proteins form a heterodimer via a
disulphide bond and salt bridge [35]. MICU2 requires the expression
of MICU1 for stability, as downregulation of MICU1 results in reduction
of MICU2 levels, implying a strong correlation in expression levels [36].
It has been suggested that MICU2 inhibits MCU opening at low [Ca2+]c
levels, sensed by the EF hands in the intermembrane space [37]. Togeth-
er, MICU1 and MICU2 establish a threshold [Ca2+]c at which MCU will
open, keeping MCU closed at low [Ca2+]c – at concentrations found at
rest in the cytosol - while the channel opens at [Ca2+]c above 2–3 μM
showing a cooperative increase in uptake as Ca2+ concentrations in-
crease as described in the earliest studies of mitochondrial Ca2+ uptake
[34,37]. Another subunit of interest is EMRE, which has been shown to
be essential for Ca2+ uptake through its interaction with both MCU
and MICU1 [38]. EMRE seems to act as a scaffolding protein and is ap-
parently required for the correct stoichiometric assembly of the com-
plex. In addition, the role of EMRE as a mitochondrial matrix Ca2+
sensor has been identiﬁed in the complex regulation of the MCU [39].
Most recently, the importance of the turnover of EMRE by an m-AAA
protease in preventing Ca2+-induced cell death was discovered [40].Please cite this article as: G. Bhosale, et al., Pathological consequences ofM
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characterised initially by knockout or overexpression in cell lines
[34,41–43]. This was followed by the discovery of a number of chil-
dren with a complex and previously unexplained disorder, includ-
ing a mild cognitive deﬁcit, neuromuscular weakness and a
progressive extrapyramidal motor disorder, all of whom showed
frame shift mutations of MICU1 [44]. Other features which have
been previously associated with mitochondrial disease were also
reported in some patients, including ataxia, microcephaly,
opthalmoplegia, ptosis, optic atrophy and peripheral axonal neu-
ropathy. More recently, two cousins with a homozygous deletion
in MICU1 were described, showing fatigue and lethargy amongst
other symptoms [45]. Cellular assays on patient ﬁbroblasts from
both reports revealed altered mitochondrial Ca2+ uptake, resulting
in increased mitochondrial Ca2+ load, but surprisingly, did not re-
veal signiﬁcant consequences on oxidative phosphorylation or
membrane potential, consistent with reports from studies in cell
lines as well as in vivo [36,43]. In addition, the mitochondrial net-
work was more fragmented in cells from the patients compared to
the controls. Unlike the MCU KO mouse, a whole body knockout of
MICU1 in the mouse has been reported to result in a high probability
of perinatal lethality in two independent studies [46,47]. Thosemice
that survived showed physical signs including ataxia and muscle
weakness as well as biochemical abnormalities, recapitulating the
pathology observed in the patients. The phenotype of these animals
improved with age, apparently related to the downregulation of
EMRE expression [47].
In the present study, we have further investigated the functional
consequences of loss ofMICU1 expression in patient derived ﬁbroblasts.
Whole exome-sequencing of the patients reported by Logan et al. re-
vealed a homozygous mutation at a splice acceptor site, c.1078-1GNC
in MICU1 in 11 of the 15 individuals and at a splice donor site,
c.741 + 1GNA in the remaining 4 patients. Experiments were carried
out in ﬁbroblasts obtained from two of the patients with the c.1078/
1GNC mutation (referred to below as ΔMICU1) and from age matched
controls.
We here propose a mechanismwhich could explain a bioenerget-
ic deﬁciency in the patients suggesting that increased Ca2+ uptake
even at resting [Ca2+]c is balanced by Ca2+ efﬂux through the
NLCX, in turn driving increased activity of the sodium proton ex-
changer. We propose that, as a consequence, an increase in proton
inﬂux across the inner membrane would undermine the proton-mo-
tive force to drive ATP synthesis by the ATP synthase. We provide ev-
idence for the existence of a futile mitochondrial Ca2+ cycle in
patient derived ﬁbroblasts and to show that this cycle impairs ATP
synthesis through oxidative phosphorylation.2. Material and methods
2.1. Cell culture
Humanﬁbroblastswere obtained frompatient and control skin sam-
ples, from a previously published report [44]. The previous study was
approved by the boards of the Leeds East and Great Ormond Street Hos-
pital research ethics committees (references Leeds East 07/H1306/113
and GOSH 00/5802, respectively) and the institutional review board of
the University of Leiden.
Cells were grown in Dulbecco's modiﬁed Eagle's medium
(DMEM: 4.5 g/L glucose and pyruvate) containing 10% foetal bovine
serum (FBS) and 1% penicillin/streptomycin (5000 U/mL, Gibco
15070-063) at 37 °C in 5% CO2. Where galactose conditions are indi-
cated, ﬁbroblasts were cultured in zero glucose DMEMwith 4 mM L-
glutamine (Invitrogen), 10% FBS (Invitrogen), 1 mM sodium pyru-
vate (Sigma), 0.1% w/v (5.5 mM) galactose (MP Biomedicals) and
1% PS (Invitrogen).ICU1mutations onmitochondrial calcium signalling and bioenergetics,
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Following relevant drug treatment and/or media changes, ﬁbro-
blasts were washed with PBS, scraped and centrifuged. Cell pellets
were then lysed in RIPA buffer (150 mM NaCl, 0.5% sodium
deoxycholic acid, 0.1% SDS, 1% Triton X-100, 50 mM Tris pH 8,
1 mM PMSF, PhosSTOP phosphatase inhibitors (Roche)) for 30 min
on ice. Samples were subsequently centrifuged at 16,000 g at 4 °C
and protein concentrations determined using Pierce BCA assay
(Thermo Scientiﬁc).
When using antibodies for detecting phosphorylation, 15–40 μg
of protein was boiled at 95 °C for 5 mins in NuPAGE 4X LDS sample
buffer (Invitrogen) containing 5% β-mercapethanol. Proteins were
separated using 4–12% NuPAGE Bis-Tris gels (Invitrogen) with
MOPS running buffer (Invitrogen) and transferred onto nitrocellu-
lose membranes using NuPAGE transfer buffer (Invitrogen) supple-
mented with 20% methanol. Membranes were washed with TBS-T
and blocked with 3% BSA in TBS-T for 1 h at RT, followed by overnight
incubation with primary antibody. Following 3 × 10 min washes in
TBS-T, membranes were incubatedwith secondary antibody solution
for 1–1.5 h at RT. After 3 × 5 min washes in TBS-T, the membranes
were developed using Amersham ECL reagent (GE Healthcare) and
imaged with a ChemiDoc system (BioRad). Densitometry analysis
was carried out using ImageJ. For detecting EMRE expression levels,
50 μg of protein was boiled and processed as above, the only differ-
ences being the use of 12% NuPAGE Bis-Tris gels, polyvinylidene ﬂuo-
ride (PVDF) membrane and 5% milk in TBS-T as the blocking buffer.
Primary antibodies used were anti-C22orf32 Antibody (C-12) (rab-
bit, Santa Cruz, 1:100), anti-DRP1 (mouse, Abcam; 1:1000), anti-
phospho DRP1 (Ser637) (rabbit, NEB; 1:1000), anti-LC3b (rabbit, Cell
Signaling; 1:2000), anti-β-actin (mouse, Santa Cruz; 1:2000), anti-
PDH E1α (mouse, Invitrogen; 1:1000) and anti-phospho PDH E1α
(Ser293) (rabbit, Novus Biologicals; 1:1000). Secondary antibodies
used were anti-mouse and anti-rabbit (both from Thermo Scientiﬁc
and diluted 1:4000).
In order to assess the PDH state and minimise variability relating to
substrate supply, protein samples were made approximately 2 h after
refreshing the culture media. Culture plates were also snap frozen at
−80 °C before scraping to minimise any subsequent kinase and phos-
phatase activity. Western blotting for phosphorylated PDH (pPDH)
was carried out ﬁrst and then the same membrane was washed and
re-probed overnight for total PDH. The proportion of pPDH was then
expressed as average intensity of pPDH band / average intensity of
total PDH band. For the DCA experiments, plated cells were treated
with 0, 2.5 and 5mMsodiumdichloroacetate, 98% (DCA) (347795) con-
centrations (neutralised with 1 M NaOH) respectively for two hours
prior to whole cell solubilisation.2.3. Assessing mitochondrial Ca2+ dynamics
Cells were plated one day before imaging on 22-mmglass coverslips
in 6-well plates (100,000 cells perwell). Cells were incubatedwith 5 μM
rhod-FF AM (Life Technologies, R23983) dyes supplemented with
0.002% pluronic acid, in recording buffer (Glucose, 10 mM; NaCl,
150 mM; KCl, 4.25 mM; NaH2PO4, 1.25 mM; NaHCO3, 4 mM; CaCl2,
1.2 mM; MgCl2, 1.2 mM; HEPES, 10 mM) at room temperature for
30 min. Prior to imaging, the dye was washed off and the solution was
replaced with recording buffer. Images were acquired on a Zeiss 700
CLSM (excitation at 555 nm, emission at N560 nm) using a 40× objec-
tive and a 37 °C heated stage.
ImageJ was used for image analysis. ROIs were drawn around indi-
vidual cells and a threshold was applied to the images to quantify the
mean intensity of the signal localised to the mitochondria within each
cell. Identical acquisition settings and threshold values were used in
all experiments.Please cite this article as: G. Bhosale, et al., Pathological consequences ofMI
Biochim. Biophys. Acta (2017), http://dx.doi.org/10.1016/j.bbamcr.2017.02.4. Oxygen consumption measurements
Oxygen consumption rates were measured using the Oroboros
Oxygraph-2K (Oroboros Instruments, Innsbruck, Austria). The sensors
in each chamber were calibrated in the respiration medium, prior
to the experiment. Cells were trypsinised and resuspended at
1million cells/mL inDMEMbufferedwith 20mMHEPES, supplemented
with 5.5 mM glucose (or 5.5 mM galactose for galactose-grown cells),
2mMglutamine and 1mMpyruvate. The cellular suspensionwasmain-
tained at 37 °C and stirred at 750 rpm. Drug additions were performed
using Hamilton syringes. Once resting rate had stabilised, 10 μM
histamine was added to induce a Ca2+−dependent rise in O2 consump-
tion. After returning to resting rate, 2.5 μM oligomycin A was added to
measure leak respiration, 1 μM FCCP to determine maximal oxidative
capacity and 2.5 μM antimycin A to measure non-mitochondrial
(background) O2 consumption. Data were acquired and analysed
using the DatLab 5 software and each of the respiratory states was
deﬁned as the average value over a region of stabilised signal.
2.5. Measuring ATP levels in the cells
ATPwasmeasured using the CellTiter-Glo Luminescent Cell Viability
Assay (Promega, G7570) protocol. This protocol is based on the princi-
ple that bioluminescence is producedwhen the enzyme luciferase catal-
yses the reaction between luciferin (both present in the assay buffer)
and ATP present in the cell. The luminescent signal is proportional to
the amount of ATP present. Cells were seeded in white 96 well plates
(20,000 cells/well) and the next day were incubated with one of the
following treatments for 1 h at 37 °C: 1 μL/mL DMSO, 5 μM oligomycin
A, 1 mM iodoacetic acid (IAA), 10 μM CGP-37157 or 10 mM 2-
deoxyglucose (DG). The cells were allowed to equilibrate at RT before
incubating with CellTiter-Glo® Reagent (Promega) for 10 min. Lumi-
nescence values proportional to ATP content were measured in a plate
reader (Fluostar Optima, BMG Labtech) using a luminescence optic
with 3 mm diameter light guide. Each condition was carried out with
a minimum sample size of 3 per replicate.
2.6. Statistics
Statistical analysis was performed using Prism 6 (GraphPad soft-
ware). Values are presented asmean± standard error. N numbers indi-
cate number of independent repeat experiments unless otherwise
indicated. Where the means of two independent groups were being
compared e.g. control group v ΔMICU1 group, two tail t-tests were ap-
plied to test signiﬁcance to a P value of 0.05. Where the means of
three or more independent groups were being compared, one-way
analysis of variance (ANOVA)wasused.When the effect of two different
independent variables was beingmeasured e.g. cell line and drug treat-
ment, two-way ANOVA was used. When several comparisons between
groups were being made, appropriate post hoc tests were used to cor-
rect for multiple testing.
3. Results
3.1. MICU1 mutations lead to a futile Ca2+ cycle
Wehave shownpreviously thatﬁbroblasts frompatientswithmuta-
tions inMICU1 showed an increase in resting [Ca2+]m, an increased rate
of mitochondrial Ca2+ uptake in response to stimulation but no change
in peak Ca2+ accumulation [44]. In trying to understand how and why
such a change in Ca2+ homeostasis might give rise to the disorder
seen in the children, we considered whether loss of MICU1 might in-
crease susceptibility to Ca2+ induced cell death. Experiments using
thapsigargin to promote Ca2+ induced cell death failed to show any sig-
niﬁcant difference between thapsigargin induced death in controls or inCU1mutations onmitochondrial calcium signalling and bioenergetics,
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cell death in ﬁbroblasts were very low.
Furthermore, it has been suggested that MICU1 knockout in cell
models increases rates of ROS generation, whichmight contribute to in-
creased cell death [48]. We therefore measured rates of ROS generation
using dihydroethidium. We found no evidence of increased oxidative
stress in the patient derived ΔMICU1 cells compared to controls (see
supplementary methods and Fig. S1).
We therefore wondered whether cellular energetics might be
undermined by a futile mitochondrial Ca2+ cycle. In patients, increased
mitochondrial Ca2+ uptake at rest through a loss of the threshold, ‘gate-
keeping’ function of MICU1 raises [Ca2+]m. Increased matrix [Ca2+] will
inevitably activate the NCLX, promoting Ca2+ efﬂux from the matrix.
The concomitant increase in Na+ ﬂux will in turn stimulate the Na+/
H+ exchange (NHX), compromising the proton gradient available for
ATP production (Fig. 1).
In order to determinewhether a futile Ca2+ cycle is active, the rate of
mitochondrial Ca2+ uptake was measured by imaging control and
ΔMICU1 ﬁbroblasts loaded with the low afﬁnity mitochondrial Ca2+ in-
dicator rhod-FF AM following inhibition of the NCLX using CGP-37157.
Average resting rhod-FF intensity was 38.6% ± 0.9 higher in the
ΔMICU1 cells than in control (P b 0.0001), consistent with the previous
studies reporting thatmitochondria are Ca2+ loaded at rest [44] (Fig. 2A,
Supplementary Fig. S2). Immediately after exposure to CGP-37157,
[Ca2+]m started to rise in the patient cells, increasingmuchmore slowly
or not at all in control cells (Fig. 2B & C). The rate of increase of rhod-FF
intensity in the patient cells was 8.9% ± 1.8 per minute compared to
2.1% ± 0.5 per minute in the control cells (Fig. 2D). It seems likely
that the plateau in the rhod-FF signal represents saturation of the dye
rather than true saturation of matrix [Ca2+]. These data conﬁrm the ac-
tivity of a continuous inﬂux pathway in patient derived mitochondria,
consistent with the presence of a futile Ca2+ cycle.
3.2. A futile Ca2+ cycle in ΔMICU1 cells undermines oxidative ATP
generation, masked by enhanced glycolysis
We previously reported that no differences were detected in the ox-
ygen consumption rate (OCR) between patient derived cells andFig. 1. Schematic diagram to demonstrate the futile Ca2+ cycle establish
Please cite this article as: G. Bhosale, et al., Pathological consequences ofM
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[44]. This is surprising, as one would expect a higher OCR in patient
cells as a result of increased PDH activity and an increased leak
reﬂecting the futile Ca2+ cycle. In an attempt to force the very glycolytic
ﬁbroblasts to adopt a more oxidative phenotype, cells were grown in
galactose. However, no signiﬁcant differences were seen between con-
trol and ΔMICU1 cells grown in galactose (Fig. 3 A). Furthermore, hista-
mine stimulation did not change OCR signiﬁcantly between the
galactose-grown control and ΔMICU1 cells (Fig. 3 B). This could be at-
tributed to theﬁbroblasts being highly glycolytic, as described previous-
ly [49]. In order to further assess the contribution of mitochondria to
cellular ATP production, we measured ATP production in the patient
and control ﬁbroblasts grown in either glucose or galactose. Galactose
is metabolised at a much slower rate than glucose, therefore forcing
the cells to utilise glutamine and shift towards oxidative phosphoryla-
tion, resulting in increased OCR compared to cells grown in glucose
[50]. Dependence of ATP generation on mitochondrial oxidative phos-
phorylation was signiﬁcantly increased in ΔMICU1 cells compared to
control cells, indicated by an increased sensitivity to oligomycin, an
ATP synthase inhibitor (***P b 0.001) (Fig. 3 C). This shows that under
conditions where aerobic glycolysis is reduced, ΔMICU1 cells are more
reliant on mitochondrial oxidative phosphorylation to produce ATP
compared to controls.
It should be noted that despite being grown in galactose, glycolysis
still contributed to the bulk of ATP production in all cells, as inhibition
of glycolysis in the presence of pyruvate caused a signiﬁcant decrease
in ATP, including application of IAA, an inhibitor of glyceraldehyde 3-
phosphate dehydrogenase (***P b 0.0001) as well as pre-treating cells
for an hour with 10 mM 2-deoxyglucose, a glycolysis inhibitor
(***P b 0.0001) (Supplementary Fig. S3). It seems plausible that a futile
Ca2+ cycle undermines ATP generated by oxidative phosphorylation in
ΔMICU1 cells, but that this is compensated at a steady state by increased
glycolytic ATP generation. We therefore measured ATP content of the
cells before and after inhibition of the NCLX with CGP-37157. In
ΔMICU1 cells, CGP-37157 caused a small but signiﬁcant increase in
ATP (108% ± 1.9) while in control cells, the inhibitor caused no signiﬁ-
cant change in ATP (95.6% ± 4.9) (P= 0.04) (Fig. 3 D). These ﬁndings
are consistent with the proposed futile Ca2+ model.ed in the absence of MICU1, resulting in a deﬁcit in ATP production.
ICU1mutations onmitochondrial calcium signalling and bioenergetics,
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Fig. 2. Effect of blocking the NCLX onmitochondrial Ca2+ uptake. (A) Representative traces of one experimental day, after normalising each time point to the resting rhod-FF intensity of
the control. (B) Representative confocal images of galactose-cultured, rhod-FF loaded control [1] and ΔMICU1 [2] ﬁbroblasts after approximately 7 mins of 10 μM CGP-37157 incubation.
(C) The initial rate of increase was analysed as percentage change per minute over the ﬁrst 2 min, after normalising to baseline of each cell. n N 100 cells from 3 independent experiments
(***P ≤ 0.001).
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nase activity
The impact of a futile mitochondrial Ca2+ cycle might to some ex-
tent be balanced by Ca2+ dependent activation of the TCA cycle due
to a high resting matrix [Ca2+], and so the net bioenergetic effect is
difﬁcult to predict and may also vary between cell types, dependingPlease cite this article as: G. Bhosale, et al., Pathological consequences ofMI
Biochim. Biophys. Acta (2017), http://dx.doi.org/10.1016/j.bbamcr.2017.0on the capacity of the TCA cycle. Increased [Ca2+]m is expected to re-
sult in activation of the three mitochondrial dehydrogenases in the
TCA cycle; isocitrate dehydrogenase, alpha-ketoglutarate dehydro-
genase and pyruvate dehydrogenase [9]. The activity of PDH was
assessed by measuring its phosphorylation at E1α S293, a site phos-
phorylated by pyruvate dehydrogenase kinase. To account for possi-
ble differences in the amount of enzyme expressed in each cell line,CU1mutations onmitochondrial calcium signalling and bioenergetics,
1.015
Fig. 3. Effect of loss of function ofMICU1 on oxygen consumption rate andATP production. (A)Oxygen consumption rate ofΔMICU1 and controlﬁbroblasts grown in glucose and galactose.
(B) Oxygen consumption rate of ΔMICU1 and control ﬁbroblasts after 10 μM histamine stimulation. Leak was measured following the addition of 2.5 μM oligomycin A and maximal
respiratory capacity was measured following addition of 1 μM FCCP. n= 6 replicates pooled from both cell lines (2 control and 2 ΔMICU1 cell lines were measured on 3 experimental
days). (C) Measurements of cellular ATP: ΔMICU1 and control ﬁbroblasts grown in glucose or galactose were pre-treated with DMSO, 5 μM oligomycin and 1 mM IAA. (D) Cells were
treated with DMSO and 10 μM CGP-37157 for 60 min. before having total ATP content quantiﬁed. Luminescence values were normalised to DMSO treatment. n= 6 replicates pooled
from both cell lines (2 control and 2 ΔMICU1 cell lines were measured on 3 experimental days) (*P ≤ 0.05, ***P ≤ 0.001).
6 G. Bhosale et al. / Biochimica et Biophysica Acta xxx (2017) xxx–xxxthe ratio of pPDH intensity to total PDH intensity was quantiﬁed. In
keeping with elevated resting [Ca2+]m and enhanced Ca2+ activated
PDP activity, the pPDH/PDH ratio was signiﬁcantly reduced in
ΔMICU1 cells (0.48 ± 0.097) compared to controls (1.00 ± 0.13)
(P = 0.0064) (Fig. 4 A & B). Treating cells with dichloroacetic acid,
an inhibitor of pyruvate dehydrogenase kinase, signiﬁcantly reduced
the phosphorylation in controls at both 2.5 mM (0.48 ± 0.07,
P b 0.05) and 5 mM (0.44 ± 0.08, P b 0.05) compared to the absenceFig. 4. PDH is dephosphorylated inΔMICU1 cells. (A)Whole cell lysates were immunoblotted fo
normalised to the average control ratio on each experimental day. n=8 replicates pooled from
(** P b 0.01). (C) Schematic diagram to demonstrate the regulation of PDH activity by Ca2+. D
Pyruvate dehydrogenase phosphatase (PDP), which increases PDH activity, is physiologica
extraction. n= 5 for controls and n= 4 for patients pooled from both cell lines (1 control and
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Furthermore, the pPDH/PDH ratios in the ΔMICU1 cells for no drug
treatment were comparable to phosphorylated state in the treated
controls, implying that PDH is already maximally active in cells lack-
ing MICU1 (Fig. 4 D). This agrees with our previous observations that
loss of MICU1 results in increased reduced state of the NADH/NAD+
pool at rest, reﬂecting Ca2+ dependent upregulation of the TCA cycle
[44].r pPDH (PDH-E1α pS293) and total PDH (PDH-E1α). (B) The ratio of band intensities was
both cell lines (2 control and 2ΔMICU1 cell lines weremeasured on 4 experimental days)
CA inhibits PDH kinase, therefore effectively activating PDH by limiting phosphorylation.
lly activated by Ca2+. (D) Cells were pre-treated with DCA before performing protein
1 ΔMICU1 cell line on 4 separate days) (* P b 0.05, ** P b 0.01).
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Fig. 5. Levels of EMREexpression in control andΔMICU1ﬁbroblasts (A)Whole cell lysateswere immunoblotted for EMREand beta-actin (B)The ratio of band intensitieswas normalised to
beta actin as the loading control on each experimental day. n=8 replicates (2 control and 2ΔMICU1 cell lines weremeasured on 4 experimental days) (2 control and 2ΔMICU1 cell lines
on 4 separate days) (** P b 0.01).
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EMRE
The stability of theMCU complex has been linked to interactions be-
tween the different gatekeepers such asMICU1, MICU2 and EMRE, most
notably in the direct correlation betweenMICU1 andMICU2 protein ex-
pression where loss of MICU1 leads to a downregulation in MICU2
levels. Previously, we have shown that loss of MICU1 expression did
not inﬂuence the levels of MCU protein [44]. Furthermore, electron
chain complex activities were not altered [44]. The role of EMRE in the
formation of the complex is not fully elucidated, but has been shown
to be important in interactions between the MICU1-MICU2 and MCU
complex. The ΔMICU1 cells showed a signiﬁcantly higher expression
of EMRE compared to the controls (controls: 0.18 ± 0.095, ΔMICU1:
1.09 ± 0.085), consistent with data from the MICU1 KOmouse (Fig. 5).
3.5. Mitochondrial fragmentation observed in patient cells lackingMICU1 is
a result of increased mitochondrial ﬁssion
Wehave previously reported that mitochondria were fragmented in
the ΔMICU1 patient cells compared to the controls [44]. In order to in-
vestigate the upstream and downstream pathways regulating theFig. 6. Immunoblots from whole cell lysates from galactose-cultured control and ΔMICU1 cel
normalised to the average control ratio on each experimental day. n = 8 replicates pooled fr
days). (C) Immunoblots for LC3. Cells were treated with 1 μL/mL DMSO (NT) or 100 nM baﬁ
14 kDa was normalised to b-actin loading control. n = 6 replicates pooled from both cell
P b 0.001, **** P b 0.0001).
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we ﬁrst assessed the phosphorylation status of S637 (inhibitory phos-
phorylation site) of DRP1. Dynamin-related protein 1 (DRP1) is a cyto-
solic GTPase, which is recruited to the mitochondria and drives ﬁssion
[51]. The ratio of total pDRP1 intensity to total DRP1 intensity was sig-
niﬁcantly reduced in the patient cells (0.39 ± 0.06) when compared
to controls (1.00 ± 0.08) (P b 0.0001) (Fig. 6 A & B). This suggests that
DRP1 is more active in the patient cells, therefore upregulating mito-
chondrial ﬁssion.
Fragmentation of the mitochondrial network could result from
impaired removal of fragmented mitochondria by autophagy [52]. To
assess autophagic ﬂux under basal conditions, the amount of LC3-II
wasmeasured in DMSO and baﬁlomycin treated control andΔMICU1ﬁ-
broblasts. Baﬁlomycin, an inhibitor of the vacuolar H+ATPase which
therefore prevents fusion of autophagosomes with lysosomes and
thus prevents their degradation, signiﬁcantly increased the level of
LC3-II in both control (P = 0.001) and ΔMICU1 cells (P b 0.0001).
Therewas no signiﬁcant difference (P=0.827) in basal LC3-II levels be-
tween control (0.17 ± 0.02) and ΔMICU1 cells (0.26 ± 0.01), nor was
there a signiﬁcant difference between control (0.76 ± 0.05) and
ΔMICU1 cells (1.05± 0.03) (P=0.051) in LC3-II levels following expo-
sure to baﬁlomycin (Fig. 6 C&D).ls. (A) Immunoblot of DRP1 (S637) and total DRP1. (B) The ratio of band intensities was
om both cell lines (2 control and 2 ΔMICU1 cell lines were measured on 4 experimental
lomycin A1 (BAF) for 5 h prior to protein extraction. (D) Intensity of the LC3-II band at
lines (2 control and 2 ΔMICU1 cell lines were measured on 3 experimental days) (***
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The sigmoid dependence of mitochondrial Ca2+ uptake on [Ca2+]c
was established over 50 years ago, but only very recently have we
begun to understand how this relationship is deﬁned through the regu-
lation of MCU opening by MICU1 and MICU2, while the disease pheno-
type caused by its failure in children with MICU1 mutations highlights
its functional importance. Our own and other recently published data
suggest that the MICU1/MICU2 complex prevent mitochondrial Ca2+
uptake at resting cytosolic [Ca2+], acts to discriminate ‘signiﬁcant’
Ca2+ signals fromnoise and protectsmitochondria fromunwanted con-
sequences of increased mitochondrial Ca2+ uptake at rest [34]. Given
the Ca2+ dependent upregulation of the TCA cycle that accompanies a
rise in matrix [Ca2+], that should increase oxidative phosphorylation,
the observation that a futile Ca2+ cycle consequent on loss of MICU1
function is sufﬁcient to undermine oxidative phosphorylation high-
lights the energetic costs of mitochondrial Ca2+ signalling, an aspect
that has been somewhat neglected. It seems plausible that the relative
contributions of these two opposing mechanisms may differ between
cells and tissues depending on the capacity of the TCA cycle, the capacity
of the respiratory chain to respond, and the activity of the NCLXmay all
differ between cell types and so deﬁne the tissues affected in the pa-
tients with MICU1 mutations.
The presence of a futile Ca2+ cycle was conﬁrmed by the simple ex-
periment of blocking the efﬂux pathway, using CGP37157 to inhibit the
NCLX. This revealed the continuous constitutive Ca2+ inﬂux into themi-
tochondria in patient derived cells, as the matrix Ca2+ concentration
rose immediately after inhibition of the extrusion pathway. To our
knowledge, this is the ﬁrst time that a futile mitochondrial Ca2+ cycle
has been directly demonstrated in a human disease, although themech-
anism has been widely considered [53,54]. Differences in pPDH/PDH
ratio between controls and patients conﬁrmed the increase in resting
matrix Ca2+ in the patient derived cells, and has been described in the
other cohort of patients lackingMICU1 [45], contrasting with the effect
of MCU KO on PDH phosphorylation [28]. Treatment with DCA, an acti-
vator of PDH, suggested that PDH was already maximally activated in
patients compared to controls, as DCA did not decrease the inhibitory
phosphorylated state of the enzyme.
Understanding the impact of MICU1 loss on ATP homeostasis in the
ﬁbroblasts is difﬁcult as the cells show a strong dependence on glycoly-
sis for ATP production. Growing the cells in galactose, forced the cells to
become more reliant on oxidative phosphorylation and so aids the de-
tection of defects in mitochondrial respiration [50]. The patient cells
showed a stronger dependence on oxidative phosphorylation for ATP
production than controls. That this is undermined signiﬁcantly by the
futile Ca2+ cycle was conﬁrmed by the small but signiﬁcant increase
in ATP seen in the patient cells following inhibition of the cycle using
CGP-37157, while in the control cells, if anything, the drug caused a
small decrease in ATP. It seems likely that the loss of the gatekeeping
function inmitochondrial Ca2+ uptakewould compromise themetabol-
ic response to increased energy demand in theΔMICU1 cells, with a par-
ticular impact on neurons and muscle, which show a very big dynamic
range of metabolic activity.
The stoichiometry and stability of theMCU complex is currently still
being investigated. Increased EMRE levels in the cells lacking MICU1
might indicate a relationship between MICU1 and EMRE expression.
Our data is consistent with the MICU1 KOmouse, where EMRE expres-
sion was directly correlated with severity of symptoms [47]. Whether
loss of MICU1 affects protein expression, stability of the EMRE subunits
or inﬂuences proteolytic pathways that prevent EMRE turnover as seen
in Konig et al., is yet to be seen.
Perturbations in mitochondrial fusion-ﬁssion dynamics have been
associated with disease, most notably in neurodegenerative diseases
such as Charcot–Marie–Tooth Disease and Dominant Optic Atrophy
[55]. Cytosolic Ca2+ has been known to play a role in mitochondrial
fragmentation in some studies [56,57]. We found that phosphorylationPlease cite this article as: G. Bhosale, et al., Pathological consequences ofM
Biochim. Biophys. Acta (2017), http://dx.doi.org/10.1016/j.bbamcr.2017.0at the inhibitory site of DRP1 was decreased in ΔMICU1 cells, indicating
increased DRP1 activity.We found no change in autophagic ﬂux in asso-
ciation with the mutation. Modulation of ﬁssion by altered mitochon-
drial Ca2+ homeostasis has been described in response to inhibition of
theMCU,which caused downregulation of DRP1 expression [58,59]. Ad-
ditional cytosolic factors orchestrate the role of cytosolic DRP1 in mito-
chondrial ﬁssion. Calcineurin is activated by a rise in [Ca2+]c and
dephosphorylates DRP1, linking mitochondrial fragmentation with
[Ca2+] signalling, but it isn't entirely clear how this relates to changes
in matrix Ca2+ handling. If anything, the increased rate of Ca2+ uptake
into mitochondria associated with MICU1 mutations are accompanied
by a decrease in cytosolic Ca2+, and so at present we cannot readily ex-
plain the mitochondrial morphological phenotype in the ﬁbroblasts
[44].
In conclusion, this study highlights a mechanism leading to a bioen-
ergetics deﬁcit, which could explain the pathological phenotype that
theMICU1 patients present with, and illuminates further avenues of in-
vestigation in order to delineate the underlying pathways that might
explain tissue speciﬁc responses to this loss-of-function mutation.
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